

Announcement Summary

Entity name

BOTANIX PHARMACEUTICALS LTD

Date of this announcement

Wednesday September 13, 2023

The +securities the subject of this notification are:

♥ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

| ASX +security code | Security description | Total number of +securities to be issued/transferred | Issue date |
|----------------------------------|---|--|------------|
| New class - code to be confirmed | Unquoted options exercisable at \$0.105 each and expiring on 12 September 2026. | 2,450,000 | 12/09/2023 |
| New class - code to be confirmed | CEO Performance Rights | 56,000,000 | 12/09/2023 |

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

BOTANIX PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

Registration number

ABN

70009109755

1.3 ASX issuer code

BOT

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

13/9/2023



Part 2 - Issue details

- 2.1 The +securities the subject of this notification are:
- € +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX
- 2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☑ does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code

+Security description

New class - code to be confirmed

Unquoted options exercisable at \$0.105 each and expiring on 12 September 2026.

+Security type

ISIN code

Options

Date the +securities the subject of this notification were issued

12/9/2023

Will all the +securities issued in this class rank equally in all respects from their issue date?
☑ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

✓ No

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

☑ No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer Notice of 2022 AGM - https://announcements.asx.com.au/asxpdf/20221021/pdf/45gkp0s2trhxds.pdf (Resolution 7 - Approval of Employee Incentive Plan).

Options Details

+Security currency

Exercise price

Expiry date

AUD - Australian Dollar

AUD 0.10500000

12/9/2026

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

Description

BOT: Fully paid ordinary shares

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer Notice of 2022 AGM - https://announcements.asx.com.au/asxpdf/20221021/pdf/45gkp0s2trhxds.pdf (Resolution 7 - Approval of Employee Incentive Plan).



Any other information the entity wishes to provide about the +securities the subject of this notification

Issue of options under the Company's Employee Incentive Plan approved by shareholders at the 2022 Annual General Meeting to employees.

Issue details

Number of +securities

2.450.000

ASX +security code +Security description

New class - code to be confirmed CEO Performance Rights

+Security type ISIN code

Other

Date the +securities the subject of this notification were issued

12/9/2023

Will all the +securities issued in this class rank equally in all respects from their issue date?

✓ Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

✓ Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP Name of registered holder Number of +securities

Howard McKibbon | Howard McKibbon | 56,000,000

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Refer ASX announcement of 25 August 2023 at https://announcements.asx.com.au/asxpdf/20230825/pdf/05t1tvrs0c41d5.pdf.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Refer Notice of 2022 AGM - https://announcements.asx.com.au/asxpdf/20221021/pdf/45gkp0s2trhxds.pdf (Resolution 7 - Approval of Employee Incentive Plan).



Any other information the entity wishes to provide about the +securities the subject of this notification

Issue of performance rights to the CEO Dr Howie McKibbon as noted in the ASX announcement of 25 August 2023.

Issue details

Number of +securities

56,000,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

| ASX +security code and description | Total number of +securities on issue |
|------------------------------------|---|
| BOT : ORDINARY FULLY PAID | 1,421,196,813 |

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|--|---|
| BOTAAD : PERFORMANCE RIGHTS | 7,333,335 |
| BOTAD : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES | 62,041,991 |
| BOTAAC : OPTION EXPIRING 14-APR-2025 EX \$0.072 | 10,000,000 |
| BOTAAB : OPTION EXPIRING 22-MAR-2025 EX \$0.094 | 4,000,000 |
| BOTAAE : OPTION EXPIRING 13-MAR-2026 EX \$0.078 | 8,500,000 |
| BOTAAF : OPTION EXPIRING 27-JUL-2025 EX \$0.18 | 6,000,000 |
| BOTAF : OPTION EXPIRING 7-OCT-2024 EX \$0.089 | 10,000,000 |
| New class - code to be confirmed : Unquoted options exercisable at \$0.105 each and expiring on 12 September 2026. | 2,450,000 |
| New class - code to be confirmed : CEO Performance Rights | 56,000,000 |



Part 5 - Other Listing Rule requirements

- 5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?
 ☑ Yes
- 5.1a Select the number of the applicable exception in Listing Rule 7.2

13